These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19553802)

  • 41. [Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].
    Khalaim AV; Stoliarenko GE
    Vestn Oftalmol; 2007; 123(5):54-6, preceding 56. PubMed ID: 18078062
    [No Abstract]   [Full Text] [Related]  

  • 42. Value-based medicine.
    Kymes SM; Vollman D; Frick KD
    Ophthalmology; 2008 Nov; 115(11):2099; author reply 2100. PubMed ID: 19068385
    [No Abstract]   [Full Text] [Related]  

  • 43. Editorial: update on the modern management of wet age-related macular degeneration.
    Devenyi RG
    Can J Ophthalmol; 2006 Apr; 41(2):133-8. PubMed ID: 16767199
    [No Abstract]   [Full Text] [Related]  

  • 44. [Electroretinography in the diagnosis and monitoring of treatment for neovascular age-related macular degeneration: Communication 2].
    Zueva MV; Tsapenko IV; Riabina MV; Grinchenko MI; Neroeva NV
    Vestn Oftalmol; 2009; 125(4):55-9. PubMed ID: 19824452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VEGF is clearly an exciting point of attack in the treatment of neovascular diseases of the retina and choroid.
    Coimbra JC
    Ophthalmologica; 2012; 227 Suppl 1():1. PubMed ID: 22645747
    [No Abstract]   [Full Text] [Related]  

  • 47. Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis.
    Hadj-Slimane R; Lepelletier Y; Lopez N; Garbay C; Raynaud F
    Biochimie; 2007 Oct; 89(10):1234-44. PubMed ID: 17707573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VEGF inhibition: insights from preclinical and clinical studies.
    Crawford Y; Ferrara N
    Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1-mediated delivery of a short hairpin RNA targeting vascular endothelial growth factor in human retinal pigment epithelium cells.
    Lombardi G; Calistri A; Curtarello M; Giudice GL; Piermarocchi S; Prosdocimo G; Palù G; Parolin C
    Br J Ophthalmol; 2009 Feb; 93(2):244-8. PubMed ID: 19174401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ophthalmic Application of Anti-VEGF Therapy.
    Lai TYY; Cheung CMG; Mieler WF
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):479-480. PubMed ID: 29204994
    [No Abstract]   [Full Text] [Related]  

  • 51. Targeting VEGF-A to treat cancer and age-related macular degeneration.
    Ferrara N; Mass RD; Campa C; Kim R
    Annu Rev Med; 2007; 58():491-504. PubMed ID: 17052163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale for combination therapies for choroidal neovascularization.
    Spaide RF
    Am J Ophthalmol; 2006 Jan; 141(1):149-56. PubMed ID: 16386991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Wandering eye for RNAi.
    Rossi J; Zamore P; Kay MA
    Nat Med; 2008 Jun; 14(6):611. PubMed ID: 18535575
    [No Abstract]   [Full Text] [Related]  

  • 54. RNA interference: generic block on angiogenesis.
    Kalluri R; Kanasaki K
    Nature; 2008 Apr; 452(7187):543-5. PubMed ID: 18385725
    [No Abstract]   [Full Text] [Related]  

  • 55. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies.
    Schmidt-Erfurth U; Kiss C; Sacu S
    Prog Retin Eye Res; 2009 Mar; 28(2):145-54. PubMed ID: 19272333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Application of functional RNAs in human diseases].
    Tanaka Y; Kozu T
    Tanpakushitsu Kakusan Koso; 2006 Nov; 51(14 Suppl):2235-7. PubMed ID: 17471945
    [No Abstract]   [Full Text] [Related]  

  • 57. Monitoring ocular drug therapy by analysis of aqueous samples.
    Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
    Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New treatments for neovascular age-related macular degeneration: when should we use them?
    Kvanta A
    Acta Ophthalmol Scand; 2007 Feb; 85(1):5. PubMed ID: 17244203
    [No Abstract]   [Full Text] [Related]  

  • 59. [siRNA in macular degeneration].
    Callizo J; Agostini HT
    Ophthalmologe; 2010 Nov; 107(11):1077-80. PubMed ID: 20652571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Choking off a tumor's blood supply.
    Morrow T
    Manag Care; 2004 Jan; 13(1):50-1. PubMed ID: 14763283
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.